Sumatriptan: Phase I data

Data from an open-label Phase I trial in 57 patients showed that subcutaneous sumatripan administered into the thigh and abdomen using the Sumavel DosePro needle-free delivery system was bioequivalent to subcutaneous sumatriptan administered using the Imitrex STATdose needle-based autoinjector. Overall safety profiles were comparable between Sumavel DosePro and Imitrex. Data were published Headache. ...